Use of the Progestogen Challenge Test to Reduce the Risk of Endometrial Cancer
In contrast to several retrospective studies reporting an increased risk of endometrial cancer during the mid-1970s, especially in estrogen-treated postmenopausal women, the number of cancers at Wilford Hall USAF Medical Center has steadily declined despite continued estrogen use. In a 4-year study...
Gespeichert in:
| Veröffentlicht in: | Obstetrics and gynecology (New York. 1953) 1980-06, Vol.55 (6), p.732-738 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 738 |
|---|---|
| container_issue | 6 |
| container_start_page | 732 |
| container_title | Obstetrics and gynecology (New York. 1953) |
| container_volume | 55 |
| creator | GAMBRELL, R DON MASSEY, FRED M CASTANEDA, TRISTAN A UGENAS, ALDONNA J RICCI, CORRINE A WRIGHT, JEAN M |
| description | In contrast to several retrospective studies reporting an increased risk of endometrial cancer during the mid-1970s, especially in estrogen-treated postmenopausal women, the number of cancers at Wilford Hall USAF Medical Center has steadily declined despite continued estrogen use. In a 4-year study from 1975 to 1978, there were 17 adenocarcinomas of the endometrium during 10,872 patient-years of observation, for an overall annual incidence of 156.4100,000 women. The highest incidence of endometrial cancer (359.1:100,000) was found in those women using estrogens alone. The lowest incidence of cancer was observed in the estrogen-progestogen users (56.4:100,000) and was significantly lower (P |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_wolte</sourceid><recordid>TN_cdi_pubmed_primary_6446050</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>6446050</sourcerecordid><originalsourceid>FETCH-LOGICAL-p2513-a0dd85f4faebc0a9efa87c6c353aacb0b7c6effdbf07967e0c6e515d99bf85fe3</originalsourceid><addsrcrecordid>eNotUMtqwzAQFKUlTdN-QkE_IFhblm0di0kfENoSEujNyNYqdiPbQbIJ_fsqj8vuzs7OwM4NmUd5xlnM-c8tmQPEkmV5ktyTB-9_ASBKJZ-RWZokKQiYk8-tRzoYOjZIv92wQz-G0tOiUdZiv0O6CSs6DnSNeqrxfLhu_f4kWvZ66HB0rbK0UH2N7pHcGWU9Pl37gmxfl5vina2-3j6KlxU7xCLiTIHWuTCJUVjVoCQalWd1WnPBlaorqAJAY3RlIJNphhCgiISWsjJBh3xBni--h6nqUJcH13bK_ZXXvwKfXPjjYEd0fm-nI7qyQWXHpgw5QBoLYJHMwxQQO0XD-T9jyVtD</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Use of the Progestogen Challenge Test to Reduce the Risk of Endometrial Cancer</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>GAMBRELL, R DON ; MASSEY, FRED M ; CASTANEDA, TRISTAN A ; UGENAS, ALDONNA J ; RICCI, CORRINE A ; WRIGHT, JEAN M</creator><creatorcontrib>GAMBRELL, R DON ; MASSEY, FRED M ; CASTANEDA, TRISTAN A ; UGENAS, ALDONNA J ; RICCI, CORRINE A ; WRIGHT, JEAN M</creatorcontrib><description>In contrast to several retrospective studies reporting an increased risk of endometrial cancer during the mid-1970s, especially in estrogen-treated postmenopausal women, the number of cancers at Wilford Hall USAF Medical Center has steadily declined despite continued estrogen use. In a 4-year study from 1975 to 1978, there were 17 adenocarcinomas of the endometrium during 10,872 patient-years of observation, for an overall annual incidence of 156.4100,000 women. The highest incidence of endometrial cancer (359.1:100,000) was found in those women using estrogens alone. The lowest incidence of cancer was observed in the estrogen-progestogen users (56.4:100,000) and was significantly lower (P <.01) than that found in the estrogen users. The incidence of corpus malignancy in the estrogen-progestogen users was also significantly lower (P <.05) than that observed in the untreated women (248.3:100,000). The progestogen challenge test has been devised to identify postmenopausal women at greatest risk for adenocarcinoma of the endometrium. It is concluded that the use of this test will reduce the risk of endometrial cancer in both estrogen-treated postmenopausal women and women with increased endogenous estrogens.</description><identifier>ISSN: 0029-7844</identifier><identifier>EISSN: 1873-233X</identifier><identifier>PMID: 6446050</identifier><language>eng</language><publisher>United States: The American College of Obstetricians and Gynecologists</publisher><subject><![CDATA[Adenocarcinoma - chemically induced ; Adenocarcinoma - epidemiology ; Adenocarcinoma - prevention & control ; Aged ; Endometrial Hyperplasia - therapy ; Estrogens - adverse effects ; Estrogens - pharmacology ; Female ; Humans ; Medroxyprogesterone - administration & dosage ; Medroxyprogesterone - analogs & derivatives ; Medroxyprogesterone Acetate ; Menopause - drug effects ; Middle Aged ; Norethindrone - administration & dosage ; Norethindrone - analogs & derivatives ; Precancerous Conditions - therapy ; Progesterone - administration & dosage ; Prospective Studies ; Risk ; Uterine Neoplasms - chemically induced ; Uterine Neoplasms - epidemiology ; Uterine Neoplasms - prevention & control]]></subject><ispartof>Obstetrics and gynecology (New York. 1953), 1980-06, Vol.55 (6), p.732-738</ispartof><rights>1980 The American College of Obstetricians and Gynecologists</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6446050$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GAMBRELL, R DON</creatorcontrib><creatorcontrib>MASSEY, FRED M</creatorcontrib><creatorcontrib>CASTANEDA, TRISTAN A</creatorcontrib><creatorcontrib>UGENAS, ALDONNA J</creatorcontrib><creatorcontrib>RICCI, CORRINE A</creatorcontrib><creatorcontrib>WRIGHT, JEAN M</creatorcontrib><title>Use of the Progestogen Challenge Test to Reduce the Risk of Endometrial Cancer</title><title>Obstetrics and gynecology (New York. 1953)</title><addtitle>Obstet Gynecol</addtitle><description>In contrast to several retrospective studies reporting an increased risk of endometrial cancer during the mid-1970s, especially in estrogen-treated postmenopausal women, the number of cancers at Wilford Hall USAF Medical Center has steadily declined despite continued estrogen use. In a 4-year study from 1975 to 1978, there were 17 adenocarcinomas of the endometrium during 10,872 patient-years of observation, for an overall annual incidence of 156.4100,000 women. The highest incidence of endometrial cancer (359.1:100,000) was found in those women using estrogens alone. The lowest incidence of cancer was observed in the estrogen-progestogen users (56.4:100,000) and was significantly lower (P <.01) than that found in the estrogen users. The incidence of corpus malignancy in the estrogen-progestogen users was also significantly lower (P <.05) than that observed in the untreated women (248.3:100,000). The progestogen challenge test has been devised to identify postmenopausal women at greatest risk for adenocarcinoma of the endometrium. It is concluded that the use of this test will reduce the risk of endometrial cancer in both estrogen-treated postmenopausal women and women with increased endogenous estrogens.</description><subject>Adenocarcinoma - chemically induced</subject><subject>Adenocarcinoma - epidemiology</subject><subject>Adenocarcinoma - prevention & control</subject><subject>Aged</subject><subject>Endometrial Hyperplasia - therapy</subject><subject>Estrogens - adverse effects</subject><subject>Estrogens - pharmacology</subject><subject>Female</subject><subject>Humans</subject><subject>Medroxyprogesterone - administration & dosage</subject><subject>Medroxyprogesterone - analogs & derivatives</subject><subject>Medroxyprogesterone Acetate</subject><subject>Menopause - drug effects</subject><subject>Middle Aged</subject><subject>Norethindrone - administration & dosage</subject><subject>Norethindrone - analogs & derivatives</subject><subject>Precancerous Conditions - therapy</subject><subject>Progesterone - administration & dosage</subject><subject>Prospective Studies</subject><subject>Risk</subject><subject>Uterine Neoplasms - chemically induced</subject><subject>Uterine Neoplasms - epidemiology</subject><subject>Uterine Neoplasms - prevention & control</subject><issn>0029-7844</issn><issn>1873-233X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1980</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNotUMtqwzAQFKUlTdN-QkE_IFhblm0di0kfENoSEujNyNYqdiPbQbIJ_fsqj8vuzs7OwM4NmUd5xlnM-c8tmQPEkmV5ktyTB-9_ASBKJZ-RWZokKQiYk8-tRzoYOjZIv92wQz-G0tOiUdZiv0O6CSs6DnSNeqrxfLhu_f4kWvZ66HB0rbK0UH2N7pHcGWU9Pl37gmxfl5vina2-3j6KlxU7xCLiTIHWuTCJUVjVoCQalWd1WnPBlaorqAJAY3RlIJNphhCgiISWsjJBh3xBni--h6nqUJcH13bK_ZXXvwKfXPjjYEd0fm-nI7qyQWXHpgw5QBoLYJHMwxQQO0XD-T9jyVtD</recordid><startdate>198006</startdate><enddate>198006</enddate><creator>GAMBRELL, R DON</creator><creator>MASSEY, FRED M</creator><creator>CASTANEDA, TRISTAN A</creator><creator>UGENAS, ALDONNA J</creator><creator>RICCI, CORRINE A</creator><creator>WRIGHT, JEAN M</creator><general>The American College of Obstetricians and Gynecologists</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>198006</creationdate><title>Use of the Progestogen Challenge Test to Reduce the Risk of Endometrial Cancer</title><author>GAMBRELL, R DON ; MASSEY, FRED M ; CASTANEDA, TRISTAN A ; UGENAS, ALDONNA J ; RICCI, CORRINE A ; WRIGHT, JEAN M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p2513-a0dd85f4faebc0a9efa87c6c353aacb0b7c6effdbf07967e0c6e515d99bf85fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1980</creationdate><topic>Adenocarcinoma - chemically induced</topic><topic>Adenocarcinoma - epidemiology</topic><topic>Adenocarcinoma - prevention & control</topic><topic>Aged</topic><topic>Endometrial Hyperplasia - therapy</topic><topic>Estrogens - adverse effects</topic><topic>Estrogens - pharmacology</topic><topic>Female</topic><topic>Humans</topic><topic>Medroxyprogesterone - administration & dosage</topic><topic>Medroxyprogesterone - analogs & derivatives</topic><topic>Medroxyprogesterone Acetate</topic><topic>Menopause - drug effects</topic><topic>Middle Aged</topic><topic>Norethindrone - administration & dosage</topic><topic>Norethindrone - analogs & derivatives</topic><topic>Precancerous Conditions - therapy</topic><topic>Progesterone - administration & dosage</topic><topic>Prospective Studies</topic><topic>Risk</topic><topic>Uterine Neoplasms - chemically induced</topic><topic>Uterine Neoplasms - epidemiology</topic><topic>Uterine Neoplasms - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GAMBRELL, R DON</creatorcontrib><creatorcontrib>MASSEY, FRED M</creatorcontrib><creatorcontrib>CASTANEDA, TRISTAN A</creatorcontrib><creatorcontrib>UGENAS, ALDONNA J</creatorcontrib><creatorcontrib>RICCI, CORRINE A</creatorcontrib><creatorcontrib>WRIGHT, JEAN M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Obstetrics and gynecology (New York. 1953)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GAMBRELL, R DON</au><au>MASSEY, FRED M</au><au>CASTANEDA, TRISTAN A</au><au>UGENAS, ALDONNA J</au><au>RICCI, CORRINE A</au><au>WRIGHT, JEAN M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of the Progestogen Challenge Test to Reduce the Risk of Endometrial Cancer</atitle><jtitle>Obstetrics and gynecology (New York. 1953)</jtitle><addtitle>Obstet Gynecol</addtitle><date>1980-06</date><risdate>1980</risdate><volume>55</volume><issue>6</issue><spage>732</spage><epage>738</epage><pages>732-738</pages><issn>0029-7844</issn><eissn>1873-233X</eissn><abstract>In contrast to several retrospective studies reporting an increased risk of endometrial cancer during the mid-1970s, especially in estrogen-treated postmenopausal women, the number of cancers at Wilford Hall USAF Medical Center has steadily declined despite continued estrogen use. In a 4-year study from 1975 to 1978, there were 17 adenocarcinomas of the endometrium during 10,872 patient-years of observation, for an overall annual incidence of 156.4100,000 women. The highest incidence of endometrial cancer (359.1:100,000) was found in those women using estrogens alone. The lowest incidence of cancer was observed in the estrogen-progestogen users (56.4:100,000) and was significantly lower (P <.01) than that found in the estrogen users. The incidence of corpus malignancy in the estrogen-progestogen users was also significantly lower (P <.05) than that observed in the untreated women (248.3:100,000). The progestogen challenge test has been devised to identify postmenopausal women at greatest risk for adenocarcinoma of the endometrium. It is concluded that the use of this test will reduce the risk of endometrial cancer in both estrogen-treated postmenopausal women and women with increased endogenous estrogens.</abstract><cop>United States</cop><pub>The American College of Obstetricians and Gynecologists</pub><pmid>6446050</pmid><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0029-7844 |
| ispartof | Obstetrics and gynecology (New York. 1953), 1980-06, Vol.55 (6), p.732-738 |
| issn | 0029-7844 1873-233X |
| language | eng |
| recordid | cdi_pubmed_primary_6446050 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adenocarcinoma - chemically induced Adenocarcinoma - epidemiology Adenocarcinoma - prevention & control Aged Endometrial Hyperplasia - therapy Estrogens - adverse effects Estrogens - pharmacology Female Humans Medroxyprogesterone - administration & dosage Medroxyprogesterone - analogs & derivatives Medroxyprogesterone Acetate Menopause - drug effects Middle Aged Norethindrone - administration & dosage Norethindrone - analogs & derivatives Precancerous Conditions - therapy Progesterone - administration & dosage Prospective Studies Risk Uterine Neoplasms - chemically induced Uterine Neoplasms - epidemiology Uterine Neoplasms - prevention & control |
| title | Use of the Progestogen Challenge Test to Reduce the Risk of Endometrial Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T05%3A03%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_wolte&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20the%20Progestogen%20Challenge%20Test%20to%20Reduce%20the%20Risk%20of%20Endometrial%20Cancer&rft.jtitle=Obstetrics%20and%20gynecology%20(New%20York.%201953)&rft.au=GAMBRELL,%20R%20DON&rft.date=1980-06&rft.volume=55&rft.issue=6&rft.spage=732&rft.epage=738&rft.pages=732-738&rft.issn=0029-7844&rft.eissn=1873-233X&rft_id=info:doi/&rft_dat=%3Cpubmed_wolte%3E6446050%3C/pubmed_wolte%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/6446050&rfr_iscdi=true |